Aytu Biopharma (AYTU) Change in Accured Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Change in Accured Expenses data on file, last reported at -$5.9 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.9 million, down 466.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.1 million (down 291.06% YoY), and the FY2025 annual result was $886000.0, up 109.67% from the prior year.
• Change in Accured Expenses retreated to -$5.9 million in Q1 2026 per AYTU's latest filing, from $3.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $8.0 million in Q1 2023 and troughed at -$14.5 million in Q2 2022.
• A 5-year average of -$1.3 million and a median of -$1.6 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses sank 574.67% in 2022, then soared 879.88% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $2.5 million in 2022, then tumbled by 48.52% to $1.3 million in 2023, then surged by 474.23% to $7.3 million in 2024, then plunged by 52.72% to $3.5 million in 2025, then sank by 270.31% to -$5.9 million in 2026.
• Business Quant data shows AYTU's Change in Accured Expenses at -$5.9 million in Q1 2026, $3.5 million in Q4 2025, and -$1.6 million in Q3 2025.